• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Amino-acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukaemia.

作者信息

Bos J L, Toksoz D, Marshall C J, Verlaan-de Vries M, Veeneman G H, van der Eb A J, van Boom J H, Janssen J W, Steenvoorden A C

出版信息

Nature. 1985;315(6022):726-30. doi: 10.1038/315726a0.

DOI:10.1038/315726a0
PMID:2989702
Abstract

DNAs from four out of five patients with acute myeloid leukaemia (AML) tested by an in vivo selection assay in nude mice using transfected mouse NIH 3T3 cells were found to contain an activated N-ras oncogene. Using a set of synthetic oligonucleotide probes, we have detected a mutation at codon 13 in all four genes. The same codon is mutated in an additional AML DNA that is positive in the focus-formation assay on 3T3 cells. DNA from the peripheral blood of one patient in remission does not contain a codon 13 mutation.

摘要

相似文献

1
Amino-acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukaemia.
Nature. 1985;315(6022):726-30. doi: 10.1038/315726a0.
2
ras gene activation in a minor proportion of the blast population in acute myeloid leukemia.急性髓系白血病中一小部分原始细胞群体中的ras基因激活。
Oncogene. 1987;1(4):409-13.
3
Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes.通过聚合酶链反应和寡核苷酸探针分析急性髓系白血病中的RAS基因突变
Proc Natl Acad Sci U S A. 1988 Mar;85(5):1629-33. doi: 10.1073/pnas.85.5.1629.
4
12th codon mutation resulting in c-N-ras activation in acute myelogenous leukemia.第12位密码子突变导致急性髓性白血病中c-N-ras激活。
Leukemia. 1988 Feb;2(2):91-3.
5
Mutations in N-ras predominate in acute myeloid leukemia.N-ras基因的突变在急性髓系白血病中占主导地位。
Blood. 1987 Apr;69(4):1237-41.
6
A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome.骨髓增生异常综合征中N-ras癌基因第13密码子处的点突变。
Nature. 1987;327(6121):430-2. doi: 10.1038/327430a0.
7
Activation of protooncogenes in spontaneously occurring non-liver tumors from C57BL/6 x C3H F1 mice.C57BL/6×C3H F1小鼠自发产生的非肝脏肿瘤中原癌基因的激活。
Cancer Res. 1991 Feb 15;51(4):1148-53.
8
Activation mechanism of the N-ras oncogene in human leukemias detected by synthetic oligonucleotide probes.用合成寡核苷酸探针检测人类白血病中N-ras癌基因的激活机制。
Biochem Biophys Res Commun. 1987 Sep 15;147(2):870-5. doi: 10.1016/0006-291x(87)91010-2.
9
Biological properties of human c-Ha-ras1 genes mutated at codon 12.在密码子12处发生突变的人类c-Ha-ras1基因的生物学特性。
Nature. 1984;312(5989):71-5. doi: 10.1038/312071a0.
10
High frequency of N-ras activation in acute myelogenous leukemia.
Blood. 1986 Mar;67(3):753-7.

引用本文的文献

1
A Pathogenic NRAS c.38G>A (p.G13D) Mutation in RARA Translocation-negative Acute Promyelocytic-like Leukemia with Concomitant Myelodysplastic Syndrome.RARA 易位阴性急性早幼粒细胞样白血病伴伴发骨髓增生异常综合征中致病性 NRAS c.38G>A(p.G13D) 突变。
Intern Med. 2023 May 1;62(9):1329-1334. doi: 10.2169/internalmedicine.0174-22. Epub 2022 Sep 21.
2
Role of Biomarkers in FLT3 AML.生物标志物在FLT3急性髓系白血病中的作用。
Cancers (Basel). 2022 Feb 24;14(5):1164. doi: 10.3390/cancers14051164.
3
Polymorphism T81C in H-RAS Oncogene Is Associated With Disease Progression in Imatinib (TKI) Treated Chronic Myeloid Leukemia Patients.
H-RAS癌基因中的T81C多态性与伊马替尼(酪氨酸激酶抑制剂)治疗的慢性髓性白血病患者的疾病进展相关。
World J Oncol. 2015 Apr;6(2):321-328. doi: 10.14740/wjon912e. Epub 2015 Apr 12.
4
Intrinsic GTP hydrolysis is observed for a switch 1 variant of Cdc42 in the presence of a specific GTPase inhibitor.在存在特定GTP酶抑制剂的情况下,观察到Cdc42的开关1变体存在内在GTP水解现象。
Small GTPases. 2016;7(1):1-11. doi: 10.1080/21541248.2015.1123797. Epub 2016 Feb 1.
5
A novel somatic mutation in ACD induces telomere lengthening and apoptosis resistance in leukemia cells.ACD基因中的一种新型体细胞突变可诱导白血病细胞中的端粒延长和抗凋亡能力。
BMC Cancer. 2015 Sep 7;15:621. doi: 10.1186/s12885-015-1639-5.
6
A specific KRAS codon 13 mutation is an independent predictor for colorectal cancer metachronous distant metastases.一种特定的KRAS密码子13突变是结直肠癌异时性远处转移的独立预测指标。
Am J Cancer Res. 2015 Jan 15;5(2):674-88. eCollection 2015.
7
Ribosome-induced tuning of GTP hydrolysis by a translational GTPase.核糖体诱导的翻译型GTP酶对GTP水解的调控
Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):14418-23. doi: 10.1073/pnas.1412676111. Epub 2014 Sep 22.
8
Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia.HRAS 和 NRAS 中的多谱系体细胞激活突变导致镶嵌性皮肤和骨骼病变、FGF23 升高和低磷血症。
Hum Mol Genet. 2014 Jan 15;23(2):397-407. doi: 10.1093/hmg/ddt429. Epub 2013 Sep 4.
9
Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx).KRAS c.35 G > A 突变型转移性结直肠癌(MCRC)患者接受密集三联化疗加贝伐珠单抗(FIr-B/FOx)治疗预后更差。
BMC Med. 2013 Mar 4;11:59. doi: 10.1186/1741-7015-11-59.
10
Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations.KRAS 突变的计算分析:对 KRAS p.G12D 和 p.G13D 突变不同影响的意义。
PLoS One. 2013;8(2):e55793. doi: 10.1371/journal.pone.0055793. Epub 2013 Feb 20.